Literature DB >> 16546171

Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment.

Cezary Zekanowski1, Maciej P Golan, Krystiana A Krzyśko, Wanda Lipczyńska-Łojkowska, Sławomir Filipek, Anna Kowalska, Grzegorz Rossa, Beata Pepłońska, Maria Styczyńska, Aleksandra Maruszak, Dorota Religa, Mieczysław Wender, Jerzy Kulczycki, Maria Barcikowska, Jacek Kuźnicki.   

Abstract

Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes are associated with early-onset familial Alzheimer's disease (EOAD). There are several reports describing mutations in PSEN1 in cases with frontotemporal dementia (FTD). We identified two novel mutations in the PSEN1 gene: L226F and L424H. The first mutation was detected in a patient with a clinical diagnosis of FTD and a post-mortem diagnosis of AD. The second mutation is connected with a clinical phenotype of variant AD with strong FTD signs. In silico modeling revealed that the mutations, as well as mutations used for comparison (F177L and L424R), change the local structure, stability and/or properties of the transmembrane regions of the presenilin 1 protein (PS1). In contrast, a silent non-synonymous substitution F175S is eclipsed by external residues and has no influence on PS1 interfacial surface. We suggest that in silico analysis of PS1 substitutions can be used to characterize novel PSEN1 mutations, to discriminate between silent polymorphisms and a potential disease-causing mutation. We also propose that PSEN1 mutations should be considered in FTD patients with no MAPT mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546171     DOI: 10.1016/j.expneurol.2006.01.022

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  23 in total

1.  Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner.

Authors:  Kara M Neely; Kim N Green; Frank M LaFerla
Journal:  J Neurosci       Date:  2011-02-23       Impact factor: 6.167

Review 2.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

3.  Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1.

Authors:  Omar Nelson; Huiping Tu; Tianhua Lei; Mostafa Bentahir; Bart de Strooper; Ilya Bezprozvanny
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

4.  Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice.

Authors:  Hirotaka Watanabe; Dan Xia; Takahisa Kanekiyo; Raymond J Kelleher; Jie Shen
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

5.  Presenilin/gamma-Secretase and Inflammation.

Authors:  Carlos A Saura
Journal:  Front Aging Neurosci       Date:  2010-05-18       Impact factor: 5.750

6.  Novel MAPT Val75Ala mutation and PSEN2 Arg62Hys in two siblings with frontotemporal dementia.

Authors:  Maura Gallo; Carmine Tomaino; Gianfranco Puccio; Francesca Frangipane; Sabrina A M Curcio; Livia Bernardi; Silvana Geracitano; Maria Anfossi; Maria Mirabelli; Rosanna Colao; Franca Vasso; Nicoletta Smirne; Raffaele G Maletta; Amalia Cecilia Bruni
Journal:  Neurol Sci       Date:  2009-09-19       Impact factor: 3.307

7.  Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.

Authors:  Yue Wang; Nigel H Greig; Qian-sheng Yu; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2008-02-20       Impact factor: 4.673

Review 8.  APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Authors:  Susan Bookheimer; Alison Burggren
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

Review 9.  Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimer's Disease.

Authors:  Carol A Deaton; Gail V W Johnson
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Neurochemical biomarkers in Alzheimer's disease and related disorders.

Authors:  Mirko Bibl; Hermann Esselmann; Jens Wiltfang
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.